Burn Care Access Is Still Hard to Reach
DALLAS is known for healthcare innovation, and Spectral AI, Inc. (NASDAQ: MDAI) sits squarely in that space, using artificial intelligence to sharpen medical diagnostics. Its emphasis on wound care comes at a pressing moment. A recent American Burn Association (ABA) study underscores long-standing inequities in who can get to specialized burn care and how quickly they can get there.
What the ABA Study Brings Into Focus
The study highlights the barriers most sharply felt by those with the least access—especially pediatric patients and people living in rural communities. Geography and cost collide here. Long distances, limited local options, and higher transport expenses slow access to the kind of care that matters most after a burn.
Distance Makes a Difference—Especially for Children
Pediatric patients must travel an average of 30.5 miles farther than adults to reach the nearest certified burn center. That extra distance isn’t just a number. For children who often need time-sensitive, specialized care, it can mean costly air or ground transfers and a greater risk of delays along the way.
Rural Patients Face the Longest Roads
People in rural areas travel 50.02% farther than those in cities to reach burn care. The price tag climbs with the miles. Air transport in particular is markedly more expensive for rural patients, putting yet another barrier between injury and treatment.
The Hidden Cost: Time and Money
Longer trips don’t just complicate logistics; they strain household budgets and local systems. Rural patients often shoulder extended travel times and specialized transportation needs, which drive costs up precisely when care can’t wait. The conclusion isn’t complicated: strategies that bring expert burn care closer—or bring expert guidance to where patients already are—are urgently needed in regions with few or no dedicated facilities.
Closing the Gap With Technology
“Access to specialized burn centers is critical in minimizing morbidity and mortality rates associated with burn injuries,” said Peter M. Carlson, CEO of Spectral AI. “Our technology aims to empower healthcare providers by delivering rapid wound assessments, regardless of the facility type.”
DeepView®: Objective Insight at the Point of Care
Spectral AI’s DeepView® System uses advanced multispectral imaging informed by a large, clinically validated dataset to assess burn wounds quickly and objectively. The goal is straightforward: arm clinicians with immediate insight to guide treatment decisions and strengthen care pathways across settings—from large hospitals to smaller facilities that may not have burn specialists on site.
Toward More Equitable Access
The study’s message is clear: targeted interventions are needed to reduce distance and cost as obstacles to care. Everyone—regardless of location or means—should be able to receive timely, effective burn treatment when it matters most.
Moving From Study to Practice
Spectral AI recently received UKCA Authorization for the DeepView® System and plans to begin commercial sales in the UK, a step toward broader access to burn assessment tools. In parallel, the company is advancing its U.S. Burn Pivotal Study to collect extensive real-world data and evaluate how the technology performs in day-to-day clinical use.
Frequently Asked Questions
What is Spectral AI focused on?
Spectral AI applies artificial intelligence to medical diagnostics, with a particular focus on wound care and burn assessment.
How does the DeepView® System help clinicians?
DeepView® uses multispectral imaging and a clinically validated dataset to generate rapid, objective burn assessments that support treatment planning.
Why do specialized burn centers matter?
Burn centers provide expertise, resources, and protocols that help reduce complications and improve outcomes after serious burn injuries.
How do distance and transport costs affect patients?
Longer travel increases the risk of delays and raises the cost of ground and air transport, which can make timely care harder to secure—especially for rural and pediatric patients.
What steps is Spectral AI taking next?
The company has UKCA Authorization for DeepView® with plans for UK commercial sales and is progressing a U.S. Burn Pivotal Study to evaluate performance in real-world clinical settings.
